Group 1: Brain-Computer Interface (BCI) Business - The company is a leading global partner and core supplier in the cochlear implant sector, with nearly 15 years of deep collaboration in technology development and production transformation [2] - The company aims to provide comprehensive technical and product support across invasive, semi-invasive, and non-invasive BCI routes, reinforcing its competitive edge in invasive BCI implants [2] - Current revenue from the BCI business (excluding cochlear implant components) is relatively small, indicating investment risks [2] Group 2: Robotics Business - The company is actively developing humanoid robots and has initiated product technology layouts in collaboration with clients, leveraging its expertise in PEEK materials and small motor components [3] - In the surgical robot sector, the company has begun small-scale deliveries to domestic and international clients [3] Group 3: Shareholding and Financial Management - A total of 14,274,464 shares are proposed to be reduced, accounting for 2.51% of the total share capital, with 2.00% through block trading and 0.51% through competitive bidding [4] - The management emphasizes maintaining shareholder value through transparent and efficient operational strategies [4] Group 4: Injection Pen and Continuous Glucose Monitoring (CGM) Business - The company has successfully delivered adjustable insulin injection pens in bulk and signed orders for weight loss pens, with automated production lines expected to be operational in 2026 [5] - CGM products are set to enter mass delivery in Q2 2025, currently in a stable ramp-up phase, with further capacity expansion planned for 2026 [5] Group 5: Respiratory and Cochlear Implant Components - The company provides comprehensive design, development, manufacturing, and sales services for precision components and products in the medical device sector, aiming to be a global leader in medical technology services [6] - Long-term strategic partnerships with leading global companies in the home ventilator and cochlear implant markets have been established, ensuring continuous innovation and competitive advantages [7]
美好医疗(301363) - 301363美好医疗投资者关系管理信息20260120